<DOC>
	<DOCNO>NCT00002142</DOCNO>
	<brief_summary>To evaluate safety tolerance cidofovir ( HPMPC ) infusion AIDS patient relapse cytomegalovirus ( CMV ) retinitis . To determine time retinitis progression patient population . To evaluate impact cidofovir therapy visual acuity .</brief_summary>
	<brief_title>An Open-Label Study Safety Efficacy Cidofovir Treatment Relapsing Cytomegalovirus Retinitis Patients With AIDS</brief_title>
	<detailed_description>Patients randomize receive intravenous HPMPC either one dose induction maintenance high dose induction maintenance . Induction consist two consecutive weekly dos follow maintenance every week . All patient receive concomitant probenecid saline hydration . Treatment continue retinitis progression , assess retinal photograph , treatment-limiting toxicity occur .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Probenecid</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral agent . Oral trimethoprim/sulfamethoxazole . Aerosolized pentamidine . Dapsone . Fluconazole . Rifabutin . Filgrastim ( GCSF ) . Itraconazole . HIV vaccine . Patients must : AIDS . CMV retinitis , severity specify Disease Status field . Life expectancy least 3 month . Consent parent guardian le 18 year age . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known clinically significant allergy probenecid . Clinically significant cardiac disease , include symptom ischemia , congestive heart failure , arrhythmia . Other active medical problem sufficient hinder study compliance . Concurrent Medication : Excluded : Amphotericin B. Aminoglycoside antibiotic . Vidarabine . Intravenous pentamidine . CMV hyperimmune immunoglobulin . Other nephrotoxic potentially nephrotoxic agent . Other investigational agent antiCMV activity . Ganciclovir . Intravenous oral acyclovir ( except follow development herpetic lesion ) . Foscarnet . Diuretics . Prior Medication : Excluded within 2 day prior study entry : Ganciclovir foscarnet . Excluded within one week prior study entry : Amphotericin B. Aminoglycoside antibiotic . Vidarabine . Intravenous pentamidine . CMV hyperimmune immunoglobulin . Other nephrotoxic agent . Other investigational agent antiCMV activity . Excluded time : Prior systemic intravitreal HPMPC . Drug alcohol abuse consider sufficient hinder study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1995</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Probenecid</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>cidofovir</keyword>
</DOC>